Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder - Full Text View

Sponsored by:	Samsung Medical Center
Information provided by:	Samsung Medical Center
ClinicalTrials.gov Identifier:	NCT00767754

Purpose

Panic disorder is one of the most prevalent and disabling psychiatric disorders. Brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus has been reported to be related with the pathophysiology and treatment outcome in panic disorder. Paroxetine has been used as primary agent for treatment of panic disorder but there is little information on how paroxetine affects the brain function in patients with panic disorder.

The specific aim of this study is to examine the differences in brain activity between responders and nonresponders and to determine the predictor of paroxetine treatment in patients with panic disorder in terms of brain activity.

Condition	Intervention	Phase
Panic Disorder	Drug: Paxil CR	Phase IV

MedlinePlus related topics: Panic Disorder

Drug Information available for: Paroxetine Paroxetine hydrochloride Paroxetine Mesylate Dextrose

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Uncontrolled, Single Group Assignment

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:

18FDG PET, PDSS & HAM-A [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	40
Study Start Date:	January 2007
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
paroxetine cr single arm	Drug: Paxil CR 12 week treatment of Paxil(20-40mg)

Eligibility

Ages Eligible for Study:	20 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

panic disorder 20-60 years

Exclusion Criteria:

history of major psychosis (schizophrenia or bipolar disorder), social phobia, obsessive-compulsive disorder, and generalized anxiety disorder, and posttraumatic stress disorder, alcohol abuse and dependence, current regular use of benzodiazepines
less than 17 on the HAM-D

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00767754

Contacts

Contact: Eun-Ho Kang, M.D.

+82-2-3410-1384

psychotx@naver.com

Locations

Korea, Republic of
Samsung Medical Center	Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Eun-Ho Kang, M.D. +82-2-3410-1384 psychotx@naver.com

Sponsors and Collaborators

Samsung Medical Center

Investigators

Principal Investigator:

Bum-Hee Yu, M.D., Ph.D.

Samsung Medical Center

More Information

Responsible Party:	Department of Psychiatry, Samsung Medical Center ( Bum-Hee Yu, M.D. Ph.D. / Professor )
Study ID Numbers:	SMC IRB 2006-07-091
Study First Received:	October 6, 2008
Last Updated:	October 6, 2008
ClinicalTrials.gov Identifier:	NCT00767754
Health Authority:	Korea: Food and Drug Administration

Keywords provided by Samsung Medical Center:

panic disorder
paroxetine
PET

Study placed in the following topic categories:

Panic Disorder
Anxiety Disorders
Mental Disorders
Paroxetine

Additional relevant MeSH terms:

Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 16, 2009